vs

Side-by-side financial comparison of Oncology Institute, Inc. (TOI) and UNIVERSAL TECHNICAL INSTITUTE INC (UTI). Click either name above to swap in a different company.

UNIVERSAL TECHNICAL INSTITUTE INC is the larger business by last-quarter revenue ($220.8M vs $142.0M, roughly 1.6× Oncology Institute, Inc.). UNIVERSAL TECHNICAL INSTITUTE INC runs the higher net margin — 5.8% vs -5.3%, a 11.1% gap on every dollar of revenue. On growth, Oncology Institute, Inc. posted the faster year-over-year revenue change (41.6% vs 9.6%). Oncology Institute, Inc. produced more free cash flow last quarter ($2.2M vs $-19.2M). Over the past eight quarters, Oncology Institute, Inc.'s revenue compounded faster (22.5% CAGR vs 9.5%).

Oncology Institute, Inc. is a specialized healthcare enterprise focused on delivering patient-centric, evidence-based oncology care services, including advanced treatment regimens, clinical trial access, and supportive care programs. It primarily operates across the United States, serving patients with diverse cancer diagnoses and partnering with care teams to improve treatment outcomes.

Universal Technical Institute, Inc. (UTI) is a private for-profit system of technical colleges in the United States. It was established in 1965 by Robert Sweet.

TOI vs UTI — Head-to-Head

Bigger by revenue
UTI
UTI
1.6× larger
UTI
$220.8M
$142.0M
TOI
Growing faster (revenue YoY)
TOI
TOI
+31.9% gap
TOI
41.6%
9.6%
UTI
Higher net margin
UTI
UTI
11.1% more per $
UTI
5.8%
-5.3%
TOI
More free cash flow
TOI
TOI
$21.3M more FCF
TOI
$2.2M
$-19.2M
UTI
Faster 2-yr revenue CAGR
TOI
TOI
Annualised
TOI
22.5%
9.5%
UTI

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
TOI
TOI
UTI
UTI
Revenue
$142.0M
$220.8M
Net Profit
$-7.5M
$12.8M
Gross Margin
Operating Margin
-4.9%
7.1%
Net Margin
-5.3%
5.8%
Revenue YoY
41.6%
9.6%
Net Profit YoY
43.0%
-42.1%
EPS (diluted)
$-0.04
$0.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TOI
TOI
UTI
UTI
Q4 25
$142.0M
$220.8M
Q3 25
$136.6M
$222.4M
Q2 25
$119.8M
$204.3M
Q1 25
$104.4M
$207.4M
Q4 24
$100.3M
$201.4M
Q3 24
$99.9M
$196.4M
Q2 24
$98.6M
$177.5M
Q1 24
$94.7M
$184.2M
Net Profit
TOI
TOI
UTI
UTI
Q4 25
$-7.5M
$12.8M
Q3 25
$-16.5M
$18.8M
Q2 25
$-17.0M
$10.7M
Q1 25
$-19.6M
$11.4M
Q4 24
$-13.2M
$22.2M
Q3 24
$-16.1M
$18.8M
Q2 24
$-15.5M
$5.0M
Q1 24
$-19.9M
$7.8M
Operating Margin
TOI
TOI
UTI
UTI
Q4 25
-4.9%
7.1%
Q3 25
-5.9%
11.2%
Q2 25
-9.4%
6.9%
Q1 25
-9.5%
8.1%
Q4 24
-11.9%
13.6%
Q3 24
-13.9%
13.3%
Q2 24
-16.6%
4.2%
Q1 24
-19.0%
6.1%
Net Margin
TOI
TOI
UTI
UTI
Q4 25
-5.3%
5.8%
Q3 25
-12.1%
8.4%
Q2 25
-14.2%
5.2%
Q1 25
-18.8%
5.5%
Q4 24
-13.1%
11.0%
Q3 24
-16.1%
9.6%
Q2 24
-15.7%
2.8%
Q1 24
-21.0%
4.2%
EPS (diluted)
TOI
TOI
UTI
UTI
Q4 25
$-0.04
$0.23
Q3 25
$-0.14
$0.33
Q2 25
$-0.15
$0.19
Q1 25
$-0.21
$0.21
Q4 24
$-0.14
$0.40
Q3 24
$-0.18
$0.35
Q2 24
$-0.17
$0.09
Q1 24
$-0.22
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TOI
TOI
UTI
UTI
Cash + ST InvestmentsLiquidity on hand
$162.8M
Total DebtLower is stronger
$101.4M
Stockholders' EquityBook value
$-15.7M
$335.9M
Total Assets
$164.7M
$834.0M
Debt / EquityLower = less leverage
0.30×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TOI
TOI
UTI
UTI
Q4 25
$162.8M
Q3 25
$169.1M
Q2 25
$70.7M
Q1 25
$96.0M
Q4 24
$172.0M
Q3 24
$161.9M
Q2 24
$9.9M
$115.5M
Q1 24
$29.8M
$116.1M
Total Debt
TOI
TOI
UTI
UTI
Q4 25
$101.4M
Q3 25
$87.1M
Q2 25
$73.8M
Q1 25
$94.4M
Q4 24
$120.1M
Q3 24
$125.7M
Q2 24
$137.3M
Q1 24
$141.9M
Stockholders' Equity
TOI
TOI
UTI
UTI
Q4 25
$-15.7M
$335.9M
Q3 25
$-12.3M
$328.1M
Q2 25
$-9.0M
$306.8M
Q1 25
$5.1M
$293.9M
Q4 24
$3.6M
$280.0M
Q3 24
$15.5M
$260.2M
Q2 24
$29.2M
$239.4M
Q1 24
$41.3M
$232.6M
Total Assets
TOI
TOI
UTI
UTI
Q4 25
$164.7M
$834.0M
Q3 25
$163.6M
$826.1M
Q2 25
$159.8M
$740.8M
Q1 25
$164.0M
$720.4M
Q4 24
$172.7M
$753.8M
Q3 24
$179.2M
$744.6M
Q2 24
$179.6M
$706.0M
Q1 24
$204.5M
$702.1M
Debt / Equity
TOI
TOI
UTI
UTI
Q4 25
0.30×
Q3 25
0.27×
Q2 25
0.24×
Q1 25
0.32×
Q4 24
0.43×
Q3 24
0.48×
Q2 24
0.57×
Q1 24
0.61×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TOI
TOI
UTI
UTI
Operating Cash FlowLast quarter
$3.2M
$3.1M
Free Cash FlowOCF − Capex
$2.2M
$-19.2M
FCF MarginFCF / Revenue
1.5%
-8.7%
Capex IntensityCapex / Revenue
0.7%
10.1%
Cash ConversionOCF / Net Profit
0.24×
TTM Free Cash FlowTrailing 4 quarters
$-27.8M
$16.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TOI
TOI
UTI
UTI
Q4 25
$3.2M
$3.1M
Q3 25
$-12.6M
$57.1M
Q2 25
$-10.2M
$18.1M
Q1 25
$-5.0M
$-789.0K
Q4 24
$4.2M
$23.0M
Q3 24
$819.0K
$67.5M
Q2 24
$-15.7M
$10.0M
Q1 24
$-15.9M
$-2.5M
Free Cash Flow
TOI
TOI
UTI
UTI
Q4 25
$2.2M
$-19.2M
Q3 25
$-13.2M
$40.6M
Q2 25
$-11.4M
$6.8M
Q1 25
$-5.3M
$-11.7M
Q4 24
$2.4M
$19.6M
Q3 24
$417.0K
$60.0M
Q2 24
$-17.5M
$3.0M
Q1 24
$-16.5M
$-8.4M
FCF Margin
TOI
TOI
UTI
UTI
Q4 25
1.5%
-8.7%
Q3 25
-9.7%
18.3%
Q2 25
-9.5%
3.4%
Q1 25
-5.1%
-5.7%
Q4 24
2.4%
9.7%
Q3 24
0.4%
30.6%
Q2 24
-17.7%
1.7%
Q1 24
-17.4%
-4.6%
Capex Intensity
TOI
TOI
UTI
UTI
Q4 25
0.7%
10.1%
Q3 25
0.4%
7.4%
Q2 25
1.0%
5.5%
Q1 25
0.3%
5.3%
Q4 24
1.8%
1.7%
Q3 24
0.4%
3.8%
Q2 24
1.9%
4.0%
Q1 24
0.6%
3.2%
Cash Conversion
TOI
TOI
UTI
UTI
Q4 25
0.24×
Q3 25
3.04×
Q2 25
1.69×
Q1 25
-0.07×
Q4 24
1.04×
Q3 24
3.58×
Q2 24
2.01×
Q1 24
-0.32×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

TOI
TOI

Other$82.1M58%
Fee For Service$36.3M26%
Capitated Revenue$23.6M17%

UTI
UTI

UTI$142.8M65%
Concorde$78.0M35%

Related Comparisons